Dimanche, 9 Août 2020
Dernières nouvelles
Principale » Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock - Is it Overbought?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock - Is it Overbought?

16 Septembre 2017

The stock was sold at an average price of $12.87, for a total transaction of $211,968.90. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

On Thursday, July 20th, Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock.

In the transaction dated November 16, 2015, the great number of shares acquired came courtesy the Former 10% owner; Sanofi added a total of 125,000 shares at an average price of $14, amounting to approximately $1,750,000.

On Tuesday, September 5th, Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock. The shares were sold at an average price of $10.00, for a total transaction of $54,900.00.

Shares of Voyager Therapeutics, Inc. We have $16.38 PT which if reached, will make NASDAQ:VYGR worth $16.95M more. The firm's market capitalization is $385.25 million. Voyager Therapeutics has a 12-month low of $8.10 and a 12-month high of $18.25.

Voyager Therapeutics, Inc. has a 50 day moving average of 10.05 and a 200 day moving average of 10.39.

The share price of the company (NASDAQ:VYGR) was up +4.20%, with a high of 16.12 during the day and the volume of Voyager Therapeutics, Inc. shares traded was 213629. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.11). Voyager Therapeutics had a negative return on equity of 46.15% and a negative net margin of 712.22%. The company had revenue of $1.18 million for the quarter, compared to analyst estimates of $3.27 million. "(VYGR) Stock" was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/09/15/bernard-ravina-sells-16470-shares-of-voyager-therapeutics-inc-vygr-stock.html.

Congo security forces kill at least 18 Burundian refugees
Other witnesses agree more than 30 people died in the clash, with video footage showing at least that number of bodies. Kijana said, and some of the Burundians began hurling stones at the officials and members of the security forces.

Several research firms have issued reports on VYGR. DAFNA Capital Management LLC increased its stake in Voyager Therapeutics by 187.2% in the second quarter. Dimensional Fund Advisors LP now owns 98,128 shares of the company's stock valued at $879,000 after purchasing an additional 68,574 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Voyager Therapeutics by 15.6% during the first quarter. The stock witnessed 81.86% gains, 59.92% gains and 35.95% gains for the 1-month, 3-month and 6-month period, respectively. Wells Fargo & Company MN now owns 83,577 shares of the company's stock valued at $1,107,000 after purchasing an additional 44,599 shares in the last quarter. Schwab Charles Investment Management Inc. now owns 28,921 shares of the company's stock valued at $383,000 after acquiring an additional 1,026 shares during the period.

Institutional investors now hold around $157 million or 76% in VYGR stock.

A number of research analysts have issued reports on VYGR shares. They issued a "buy" rating and a $20.00 target price for the company.

News headlines about Voyager Therapeutics (NASDAQ:VYGR) have trended somewhat positive recently, Accern Sentiment reports. Chardan Capital Markets upgraded the stock to "Neutral" rating in Monday, January 25 report. Evercore ISI assumed coverage on shares of Voyager Therapeutics in a research report on Wednesday, August 16th. They now have a Dollars 21 price target on the stock.

01/06/2016 - Voyager Therapeutics, Inc. had its "overweight" rating reiterated by analysts at Piper Jaffray. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The stock was sold at an average price of $10.00, for a total transaction of $54,900.00.

03/01/2017 - Instinet began new coverage on Voyager Therapeutics, Inc. giving the company a "buy" rating.